10 August 2018
Visiongain has launched a new pharma report Global Treatment for Neglected Tropical Disease Market 2017-2027: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease
According to the Centers for Disease Control and Prevention (CDC), one hundred percent of low-income countries are affected by at least five neglected tropical diseases simultaneously. Worldwide, 149 countries and territories are affected by at least one neglected tropical disease (NTD). The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travellers or cargo. Every year, malaria alone results in one to three million deaths out of approximately half a billion cases, while many more go undetected or undiagnosed.
The lead analyst of the report commented “The treatment for neglected tropical disease market is set to experience considerable growth over the next decade. The main growth drivers include, rising awareness towards neglected tropical disease, increasing prevalence of neglected disease such as malaria and dengue as well as increasing governments’ initiatives.
There are still gaps that need to be met. Improved diagnostics for neglected tropical diseases for example, are essential for guiding treatment strategies at different thresholds of control, interruption of transmission, elimination and post-elimination surveillance.”
Leading companies featured in the report include Pfizer, Inc., Bayer, GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Takeda Pharmaceutical Company Ltd, Sanofi S.A. and Eisai Co., Ltd.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.